4 news items
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13
PASG
15 May 24
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 to $13.
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PASG
14 May 24
, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat
Canaccord Genuity Reiterates Buy on Passage Bio, Maintains $14 Price Target
PASG
5 Mar 24
Canaccord Genuity analyst Whitney Ijem reiterates Passage Bio (NASDAQ:PASG) with a Buy and maintains $14 price target.
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PASG
4 Mar 24
designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative
- Prev
- 1
- Next